We are live on
!
Find out more
NM
Newtyn Management Portfolio holdings
AUM
$936M
1-Year Est. Return
27.23%
This Fund
S&P 500
This Quarter
Est. Return
-0.44%
1 Year Est. Return
+27.23%
3 Year Est. Return
+51.99%
5 Year Est. Return
+55.23%
10 Year Est. Return
+165.15%
AUM
$509M
AUM Growth
+$24.3M
(+5%)
Cap. Flow
+$43.7M
Cap. Flow
% of AUM
8.58%
Top 10 Holdings %
Top 10 Hldgs %
47.79%
Holding
85
New
14
Increased
22
Reduced
35
Closed
5
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
G-III Apparel Group
GIII
|
+$24.1M |
| 2 |
Customers Bancorp
CUBI
|
+$13M |
| 3 |
Q2 Holdings
QTWO
|
+$8.92M |
| 4 |
TSVT
2seventy bio
TSVT
|
+$7.12M |
| 5 |
CMA
Comerica
CMA
|
+$6.73M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
AVTA
Avantax, Inc. Common Stock
AVTA
|
+$24.4M |
| 2 |
1-800-Flowers.com
FLWS
|
+$6.57M |
| 3 |
ONL
Orion Office REIT
ONL
|
+$3.56M |
| 4 |
IVAC
Intevac Inc
IVAC
|
+$3.36M |
| 5 |
MBIA
MBI
|
+$3.14M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Consumer Discretionary | 23.36% |
| 2 | Healthcare | 20.73% |
| 3 | Financials | 12.06% |
| 4 | Communication Services | 9.18% |
| 5 | Real Estate | 8.05% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
51
Bolt Biotherapeutics
BOLT
$7.67M
| $1.55M | 0.3% |
55,756
-1,744
| -3% | -$51K |
|
|
TCRR
52
DELISTED
TCR2 Therapeutics Inc. Common Stock
TCRR
| $1.52M | 0.3% |
1,015,920
-59,080
| -5% | -$79.6K |
|
53
Olema Pharmaceuticals
OLMA
$1B
| $1.3M | 0.26% |
375,000
+15,000
| +4% | +$61.2K |
|
|
ADVM
54
DELISTED
Adverum Biotechnologies
ADVM
| $1.1M | 0.22% |
152,840
-10,660
| -7% | -$75.4K |
|
|
ORKA
55
Oruka Therapeutics
ORKA
$5.82B
| $1.03M | 0.2% |
43,314
-1,543
| -3% | -$40.7K |
|
56
Alpha Metallurgical Resources
AMR
$1.74B
| $986K | 0.19% |
6,319
| – | – |
|
57
Alector
ALEC
$168M
| $959K | 0.19% |
155,000
+10,000
| +7% | +$81.3K |
|
|
LTCH
58
DELISTED
Latch, Inc. Common Stock
LTCH
| $915K | 0.18% |
1,200,000
-290,000
| -19% | -$238K |
|
59
Aligos Therapeutics
ALGS
$26.2M
| $893K | 0.18% |
40,858
-19,142
| -32% | -$731K |
|
|
FFWM
60
DELISTED
First Foundation Inc
FFWM
| $782K | 0.15% |
+105,000
| New | +$1.4M |
|
|
DBTX
61
DELISTED
Decibel Therapeutics, Inc. Common Stock
DBTX
| $767K | 0.15% |
253,818
-16,182
| -6% | -$55.9K |
|
62
Oric Pharmaceuticals
ORIC
$1.15B
| $764K | 0.15% |
133,999
-11,001
| -8% | -$57.5K |
|
63
CytomX Therapeutics
CTMX
$675M
| $642K | 0.13% |
425,000
-145,000
| -25% | -$328K |
|
64
Iovance Biotherapeutics
IOVA
$1.82B
| $642K | 0.13% |
105,000
-15,000
| -13% | -$103K |
|
65
Passage Bio
PASG
$14.4M
| $637K | 0.13% |
33,261
-6,239
| -16% | -$169K |
|
66
GeneDx Holdings
WGS
$1.93B
| $622K | 0.12% |
51,667
-8,939
| -15% | -$119K |
|
67
Black Diamond Therapeutics
BDTX
$96.8M
| $579K | 0.11% |
306,609
-8,391
| -3% | -$19.3K |
|
68
Ponce Financial Group
PDLB
$488M
| $552K | 0.11% |
+70,351
| New | +$637K |
|
69
TScan Therapeutics
TCRX
$48.6M
| $497K | 0.1% |
236,800
+6,800
| +3% | +$16.1K |
|
70
Forte Biosciences
FBRX
$1.57B
| $415K | 0.08% |
16,430
-5,520
| -25% | -$139K |
|
71
Comp X International
CIX
$349M
| $375K | 0.07% |
20,737
-34,738
| -63% | -$639K |
|
72
Columbia Financial
CLBK
$1.12B
| $358K | 0.07% |
+19,600
| New | +$397K |
|
73
Nuvation Bio
NUVB
$2.2B
| $357K | 0.07% |
215,000
-25,000
| -10% | -$50.7K |
|
|
IOBT
74
DELISTED
IO Biotech
IOBT
| $92.3K | 0.02% |
49,346
-40,654
| -45% | -$101K |
|
|
BRLIR
75
DELISTED
Brilliant Acquisition Corporation Rights
BRLIR
| $65.9K | 0.01% |
457,409
| – | – |
|
Similar funds
APM
PWAM
NI
MCM
TS
TW
PGA
FPI
Newtyn Management's Q1 2023 Portfolio in Review
As of Q1 2023, Newtyn Management held 85 positions worth $509M, up 5% from $485M the previous quarter. Its ten largest holdings account for 48% of the portfolio.
Newtyn Management deployed $43.7M of net new capital in Q1 2023, opening 14 new positions and adding to 22 existing holdings. Its largest new stake was G-III Apparel Group: 1,539,625 shares worth $23.9M.
By sector, the portfolio is most concentrated in Consumer Discretionary at 23% of assets, up from 22% a quarter earlier, followed by Healthcare and Financials.
On the sell side, the largest reduction was Avantax, Inc. Common Stock, an estimated $24.4M trimmed.
- Newtyn Management's largest Q1 2023 buy was G-III Apparel Group: 1,539,625 shares worth $23.9M.
- Newtyn Management added most to Customers Bancorp in Q1 2023, an estimated $13M increase.
- Newtyn Management's biggest Q1 2023 reduction was Avantax, Inc. Common Stock, cutting an estimated $24.4M.
- Newtyn Management fully exited Intevac Inc in Q1 2023, selling an estimated $3.36M.
- Newtyn Management's ten largest holdings make up 48% of its $509M portfolio in Q1 2023.
- Newtyn Management opened 14 new positions and closed 5 in Q1 2023.
- Newtyn Management's portfolio value rose 5% quarter-over-quarter to $509M.
Based on Newtyn Management's 13F filing for Q1 2023, filed 15 May 2023.